{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T06:25:18Z","timestamp":1783059918746,"version":"3.54.6"},"reference-count":31,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals USA Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.dld.2026.04.004","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T20:04:13Z","timestamp":1778357053000},"page":"765-772","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["FRUQUITAS trial: Study design of an ENGIC intergroup randomized phase III of trifluridine\/tipiracil +\/- fruquintinib in pre-treated metastatic gastro-oesophageal adenocarcinoma"],"prefix":"10.1016","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8065-9635","authenticated-orcid":false,"given":"David","family":"Tougeron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8915-226X","authenticated-orcid":false,"given":"Fernando","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2789-9082","authenticated-orcid":false,"given":"Tania Fleitas","family":"Kanonnikoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3226-8525","authenticated-orcid":false,"given":"Karine","family":"Le Malicot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meriem","family":"Guarssifi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadim","family":"Fares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Soularue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1366-7678","authenticated-orcid":false,"given":"Melanie","family":"Dos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Taieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8834-6927","authenticated-orcid":false,"given":"Thomas","family":"Aparicio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8475-5459","authenticated-orcid":false,"given":"Pierre","family":"Laurent-Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3253-8206","authenticated-orcid":false,"given":"Ulrich T.","family":"Hacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4630-5830","authenticated-orcid":false,"given":"Ana","family":"Fern\u00e1ndez Montes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salah-Eddin","family":"Al-Batran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Lordick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2026.04.004_bib0001","first-page":"69","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.dld.2026.04.004_bib0002","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S1470-2045(25)00130-5","article-title":"TFOX versus FOLFOX in first-line treatment of patients with advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (PRODIGE 51\u2013FFCD-GASTFOX): an open-label, multicentre, randomised, phase 3 trial","volume":"26","author":"Zaanan","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.dld.2026.04.004_bib0003","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2026.04.004_bib0004","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.dld.2026.04.004_bib0005","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078876","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma (RATIONALE-305): a randomised, double-blind, phase 3 trial","volume":"385","author":"Qiu","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.dld.2026.04.004_bib0006","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma (GLOW): a randomised, phase 3 trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.dld.2026.04.004_bib0007","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in CLDN18.2-positive, HER2-negative, untreated gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet"},{"issue":"7890","key":"10.1016\/j.dld.2026.04.004_bib0008","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41586-021-04161-3","article-title":"The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer","volume":"600","author":"Janjigian","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.dld.2026.04.004_bib0009","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1470-2045(13)70549-7","article-title":"Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial","volume":"15","author":"Ford","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.dld.2026.04.004_bib0010","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.ejca.2011.06.002","article-title":"Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer","volume":"47","author":"Thuss-Patience","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.dld.2026.04.004_bib0011","doi-asserted-by":"crossref","first-page":"4438","DOI":"10.1200\/JCO.2012.48.5805","article-title":"Irinotecan versus paclitaxel in patients with advanced gastric cancer after failure of fluoropyrimidine plus platinum","volume":"31","author":"Hironaka","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2026.04.004_bib0012","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1200\/JCO.2013.54.1011","article-title":"Prospective, randomized, multicenter phase III study of FOLFIRI versus ECF in advanced gastric adenocarcinoma","volume":"32","author":"Guimbaud","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2026.04.004_bib0013","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW)","volume":"15","author":"Wilke","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.dld.2026.04.004_bib0014","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","article-title":"Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD)","volume":"383","author":"Fuchs","year":"2014","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.dld.2026.04.004_bib0015","first-page":"223","article-title":"Survival in Advanced Esophagogastric Adenocarcinoma Improves With Use of Multiple Lines of Therapy: Results From an Analysis of More Than 500 Patients","volume":"17","author":"Davidson","year":"2018","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.dld.2026.04.004_bib0016","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/S1470-2045(18)30739-3","article-title":"Trifluridine\/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"19","author":"Shitara","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.dld.2026.04.004_bib0017","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.dld.2026.04.004_bib0018","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0235848","article-title":"Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry","volume":"15","author":"Cotes Sanch\u00eds","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.dld.2026.04.004_bib0019","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1200\/JCO.2011.36.2236","article-title":"Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer","volume":"29","author":"Ohtsu","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2026.04.004_bib0020","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1200\/JCO.2015.63.5995","article-title":"Apatinib in patients with chemotherapy-refractory advanced or metastatic gastric or gastroesophageal junction adenocarcinoma","volume":"34","author":"Li","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2026.04.004_bib0021","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1200\/JCO.2015.65.1901","article-title":"Regorafenib for the treatment of advanced gastric cancer (INTEGRATE)","volume":"34","author":"Pavlakis","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2026.04.004_bib0022","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","article-title":"Trifluridine\u2013tipiracil and bevacizumab in refractory metastatic colorectal cancer","volume":"388","author":"Prager","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2026.04.004_bib0023","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1002\/ijc.34652","article-title":"Ramucirumab beyond progression plus TAS-102 in advanced oesophagogastric adenocarcinoma","volume":"153","author":"Goetze","year":"2023","journal-title":"Int J Cancer"},{"key":"10.1016\/j.dld.2026.04.004_bib0024","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S2468-1253(20)30396-4","article-title":"Safety and activity of trifluridine\/tipiracil and ramucirumab in previously treated advanced gastric cancer","volume":"6","author":"Kawazoe","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2026.04.004_bib0025","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.2018.7855","article-title":"Effect of fruquintinib versus placebo on overall survival in patients with previously treated metastatic colorectal cancer (FRESCO)","volume":"319","author":"Li","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.dld.2026.04.004_bib0026","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0140-6736(23)00772-9","article-title":"Fruquintinib versus placebo in refractory metastatic colorectal cancer (FRESCO-2)","volume":"402","author":"Dasari","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2026.04.004_bib0027","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1038\/s41591-024-02989-6","article-title":"Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma (FRUTIGA)","volume":"30","author":"Wang","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.dld.2026.04.004_bib0028","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.21037\/tcr-23-867","article-title":"Fruquintinib in combination with TAS-102 or sintilimab in metastatic colorectal cancer: a real-world study","volume":"12","author":"Li","year":"2023","journal-title":"Transl Cancer Res"},{"key":"10.1016\/j.dld.2026.04.004_bib0029","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3390\/jcm13010057","article-title":"Trifluridine\/tipiracil with fruquintinib in chemorefractory metastatic colorectal cancer","volume":"13","author":"Zou","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.dld.2026.04.004_bib0030","doi-asserted-by":"crossref","unstructured":"Samalin E, Evesque L, Turpin A, et al. Regorafenib combined with irinotecan as second-line treatment in metastatic gastro-oesophageal adenocarcinomas: results of PRODIGE 58-UCGI35-REGIRI Unicancer randomised phase II study. ESMO Open. 2025 May;10(5):105096. doi: 10.1016\/j.esmoop.2025.105096.","DOI":"10.1016\/j.esmoop.2025.105096"},{"key":"10.1016\/j.dld.2026.04.004_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105055","article-title":"Promoting large multinational academic clinical trials for gastrointestinal cancers in Europe: the ENGIC initiative","volume":"10","author":"Taieb","year":"2025","journal-title":"ESMO Open"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865826006985?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865826006985?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T06:10:59Z","timestamp":1783059059000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865826006985"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1590865826006985"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2026.04.004","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FRUQUITAS trial: Study design of an ENGIC intergroup randomized phase III of trifluridine\/tipiracil +\/- fruquintinib in pre-treated metastatic gastro-oesophageal adenocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2026.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of Editrice Gastroenterologica Italiana S.r.l.","name":"copyright","label":"Copyright"}]}}